Synergistic interaction of diclofenac, benfotiamine, and resveratrol in experimental acute pain

Rosa Mariana Montiel-Ruiz, Vinicio Granados-Soto, Sara García-Jiménez, Gerardo Reyes-García, Francisco J. Flores-Murrieta, Myrna Déciga-Campos

Research output: Contribution to journalArticle

Abstract

This study was designed to evaluate the possible synergistic antinociceptive interactions between diclofenac, benfotiamine, and resveratrol on acetic acid-induced nociception in mice. Isobolographic analyses were used to define the nature of the interactions between drugs. Diclofenac, benfotiamine, or resveratrol, as well as their combinations, produced a dose-dependent antinociceptive effect. ED30 values were estimated for the individual drugs and isobolograms were constructed. Theoretical ED30 values for the combinations estimated from the isobolograms were 170.9±23.4, 4.9±1.0, and 173.3±11.8 mg/kg for the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination, respectively. These values were significantly higher than the actually observed ED 30 values, which were 10.2±1.9, 0.3±0.1, and 5.3±0.8 mg/kg, respectively, indicating a synergistic interaction in the three combinations. Data indicate that low doses of the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination can interact synergistically to reverse acetic acid-induced nociception and they may represent a therapeutic advantage for clinical treatment of inflammatory pain. © 2011 Wiley-Liss, Inc.
Original languageAmerican English
Pages (from-to)397-404
Number of pages356
JournalDrug Development Research
DOIs
StatePublished - 1 Jan 2011
Externally publishedYes

Fingerprint

Diclofenac
Acute Pain
Nociception
Acetic Acid
Drug Interactions
benphothiamine
resveratrol
Pain
Therapeutics
Pharmaceutical Preparations

Cite this

@article{bd17e6be668f4125a0e2898863f27a47,
title = "Synergistic interaction of diclofenac, benfotiamine, and resveratrol in experimental acute pain",
abstract = "This study was designed to evaluate the possible synergistic antinociceptive interactions between diclofenac, benfotiamine, and resveratrol on acetic acid-induced nociception in mice. Isobolographic analyses were used to define the nature of the interactions between drugs. Diclofenac, benfotiamine, or resveratrol, as well as their combinations, produced a dose-dependent antinociceptive effect. ED30 values were estimated for the individual drugs and isobolograms were constructed. Theoretical ED30 values for the combinations estimated from the isobolograms were 170.9±23.4, 4.9±1.0, and 173.3±11.8 mg/kg for the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination, respectively. These values were significantly higher than the actually observed ED 30 values, which were 10.2±1.9, 0.3±0.1, and 5.3±0.8 mg/kg, respectively, indicating a synergistic interaction in the three combinations. Data indicate that low doses of the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination can interact synergistically to reverse acetic acid-induced nociception and they may represent a therapeutic advantage for clinical treatment of inflammatory pain. {\circledC} 2011 Wiley-Liss, Inc.",
author = "Montiel-Ruiz, {Rosa Mariana} and Vinicio Granados-Soto and Sara Garc{\'i}a-Jim{\'e}nez and Gerardo Reyes-Garc{\'i}a and Flores-Murrieta, {Francisco J.} and Myrna D{\'e}ciga-Campos",
year = "2011",
month = "1",
day = "1",
doi = "10.1002/ddr.20441",
language = "American English",
pages = "397--404",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",

}

Synergistic interaction of diclofenac, benfotiamine, and resveratrol in experimental acute pain. / Montiel-Ruiz, Rosa Mariana; Granados-Soto, Vinicio; García-Jiménez, Sara; Reyes-García, Gerardo; Flores-Murrieta, Francisco J.; Déciga-Campos, Myrna.

In: Drug Development Research, 01.01.2011, p. 397-404.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Synergistic interaction of diclofenac, benfotiamine, and resveratrol in experimental acute pain

AU - Montiel-Ruiz, Rosa Mariana

AU - Granados-Soto, Vinicio

AU - García-Jiménez, Sara

AU - Reyes-García, Gerardo

AU - Flores-Murrieta, Francisco J.

AU - Déciga-Campos, Myrna

PY - 2011/1/1

Y1 - 2011/1/1

N2 - This study was designed to evaluate the possible synergistic antinociceptive interactions between diclofenac, benfotiamine, and resveratrol on acetic acid-induced nociception in mice. Isobolographic analyses were used to define the nature of the interactions between drugs. Diclofenac, benfotiamine, or resveratrol, as well as their combinations, produced a dose-dependent antinociceptive effect. ED30 values were estimated for the individual drugs and isobolograms were constructed. Theoretical ED30 values for the combinations estimated from the isobolograms were 170.9±23.4, 4.9±1.0, and 173.3±11.8 mg/kg for the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination, respectively. These values were significantly higher than the actually observed ED 30 values, which were 10.2±1.9, 0.3±0.1, and 5.3±0.8 mg/kg, respectively, indicating a synergistic interaction in the three combinations. Data indicate that low doses of the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination can interact synergistically to reverse acetic acid-induced nociception and they may represent a therapeutic advantage for clinical treatment of inflammatory pain. © 2011 Wiley-Liss, Inc.

AB - This study was designed to evaluate the possible synergistic antinociceptive interactions between diclofenac, benfotiamine, and resveratrol on acetic acid-induced nociception in mice. Isobolographic analyses were used to define the nature of the interactions between drugs. Diclofenac, benfotiamine, or resveratrol, as well as their combinations, produced a dose-dependent antinociceptive effect. ED30 values were estimated for the individual drugs and isobolograms were constructed. Theoretical ED30 values for the combinations estimated from the isobolograms were 170.9±23.4, 4.9±1.0, and 173.3±11.8 mg/kg for the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination, respectively. These values were significantly higher than the actually observed ED 30 values, which were 10.2±1.9, 0.3±0.1, and 5.3±0.8 mg/kg, respectively, indicating a synergistic interaction in the three combinations. Data indicate that low doses of the diclofenac+benfotiamine, diclofenac+resveratrol, or benfotiamine+resveratrol combination can interact synergistically to reverse acetic acid-induced nociception and they may represent a therapeutic advantage for clinical treatment of inflammatory pain. © 2011 Wiley-Liss, Inc.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80052041190&origin=inward

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=80052041190&origin=inward

U2 - 10.1002/ddr.20441

DO - 10.1002/ddr.20441

M3 - Article

SP - 397

EP - 404

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

ER -